05:28 PM EDT, 05/20/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday the US Food and Drug Administration lifted a partial clinical hold previously imposed on the clinical program to study nomlabofusp for treating Friedreich's Ataxia, an inherited nervous system disorder.

Following a review of data from Larimar Therapeutics' ( LRMR ) recent four-week Phase 2 dose exploration study, the FDA lifted the hold, the company said.

Nomlabofusp is a recombinant fusion protein that will deliver human frataxin into the mitochondria of patients with Friedreich's Ataxia.

Larimar Therapeutics ( LRMR ) shares jumped more than 23% in after-hours activity.

Price: 8.98, Change: +1.71, Percent Change: +23.52